Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.

ABSTRACT:

Objective

The Insulin Resistance Intervention after Stroke (IRIS) trial recently found that pioglitazone reduced risk for stroke and myocardial infarction in patients with insulin resistance but without diabetes who had had a recent ischemic stroke or transient ischemic attack (TIA). This report provides detailed results on the metabolic effects of pioglitazone and the trial's prespecified secondary aim of diabetes prevention.

Research design and methods

A total of 3,876 patients with recent ischemic stroke or TIA, no history of diabetes, fasting plasma glucose (FPG) <126 mg/dL, and insulin resistance by homeostasis model assessment of insulin resistance (HOMA-IR) score >3.0 were randomly assigned to pioglitazone or placebo. Surveillance for diabetes onset during the trial w

SUBMITTER: Inzucchi SE 

PROVIDER: S-EPMC5033078 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature